Brief: Botensilimab/Balstilimab Breakthrough Data Presented At Asco-Gi Shows Unprecedented Tumor Shrinkage And Robust Biomarker Response In Prevalent Colorectal Cancer Population
22/01/2024 12:53
Jan 22 (Reuters) - Agenus Inc AGEN.O :
* BOTENSILIMAB/BALSTILIMAB BREAKTHROUGH DATA PRESENTED AT
ASCO-GI
SHOWS UNPRECEDENTED TUMOR SHRINKAGE AND ROBUST BIOMARKER
RESPONSE IN PREVALENT COLORECTAL CANCER POPULATION
Source text for Eikon: ID:nBwstLKla
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income